Memantine Hydrochloride Bristol Laboratories

Memantine hydrochloride, the active ingredient in Memantine Hydrochloride Bristol Laboratories, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. The drug works by modulating glutamatergic neurotransmission, helping to preserve neuronal function and cognition.

GNH USA supplies Memantine Hydrochloride Bristol Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across EU and global markets.

Memantine is an NMDA receptor antagonist used in the management of Alzheimer’s disease.

Alzheimer’s disease: improves cognition and functional abilities in patients with moderate to severe disease.

Memantine may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools. - Confusion: transient disorientation or difficulty concentrating. - Fatigue: feeling unusually tired or weak. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: uncontrolled electrical activity in the brain. - Hallucinations: seeing or hearing things that are not present. - Cardiac arrhythmia: irregular heart rhythm that may require monitoring. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Stevens‑Johnson syndrome: rare skin disorder with blistering. - Suicidal thoughts: emergence of self‑harm ideation.

When prescribing memantine, clinicians should consider several safety factors. - Renal impairment: adjust dose or monitor renal function. - Hepatic impairment: use with caution in patients with liver disease. - History of seizures: assess risk and monitor neurological status. - Elderly patients: start at low dose and titrate slowly. - Concomitant NMDA antagonists: avoid combined use to prevent excess blockade. - Store at ambient temperature: keep in the original container, protect from moisture.

Memantine can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Dextromethorphan: combined use can cause severe CNS depression. - Ketamine: heightened risk of psychomimetic effects.

Moderate Interactions (Monitor Closely): - Donepezil: may require dose adjustment for optimal cognitive benefit. - Antihypertensives: monitor blood pressure for additive hypotensive effect. - Antipsychotics: observe for increased sedation or extrapyramidal symptoms.